B of A Securities Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Brian Cheng maintains a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) and raises the price target from $44 to $46.
October 12, 2023 | 7:25 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Apellis Pharmaceuticals' price target has been raised from $44 to $46 by B of A Securities, while maintaining a Neutral rating.
The news is directly about Apellis Pharmaceuticals. The raised price target indicates a positive outlook, but the maintained Neutral rating suggests that the analyst does not see significant upside potential in the short term. Therefore, the short term impact on the stock price is likely to be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100